NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ANIP Stock Alerts $64.76 -0.67 (-1.02%) (As of 02:40 PM ET) Add Compare Share Share Today's Range$64.29▼$65.2850-Day Range$57.55▼$69.6952-Week Range$36.99▼$70.81Volume30,096 shsAverage Volume136,349 shsMarket Capitalization$1.37 billionP/E Ratio77.10Dividend YieldN/APrice Target$80.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.3% Upside$80.00 Price TargetShort InterestHealthy1.01% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.44Based on 15 Articles This WeekInsider TradingSelling Shares$10.36 M Sold Last QuarterProj. Earnings Growth16.62%From $3.55 to $4.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector58th out of 907 stocksPharmaceutical Preparations Industry20th out of 422 stocks 2.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.01% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.5 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat Follows8 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,363,466.00 in company stock.Percentage Held by Insiders12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 16.62% in the coming year, from $3.55 to $4.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 77.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.81.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 77.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 201.39.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesApril 23, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $1,095,442.53 in StockApril 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 SharesApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 16, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,947.50 in StockApril 3, 2024 | insidertrades.comChad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockApril 24, 2024 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at GuggenheimApril 23, 2024 | markets.businessinsider.comEvaluating ANI Pharmaceuticals: Insights From 5 Financial AnalystsApril 22, 2024 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2024 Earnings GuidanceApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 19, 2024 | americanbankingnews.comMuthusamy Shanmugam Sells 7,414 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockApril 19, 2024 | americanbankingnews.comMuthusamy Shanmugam Sells 9,520 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockApril 19, 2024 | investing.comAni Pharmaceuticals executive sells over $1.5 million in company stockApril 18, 2024 | globenewswire.comANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ETApril 16, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 SharesApril 12, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is favoured by institutional owners who hold 64% of the companyApril 10, 2024 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should KnowApril 10, 2024 | stocknews.com3 Biotech Stocks Gaining Altitude and InterestApril 9, 2024 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Baclofen Oral SuspensionApril 9, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Baclofen Oral SuspensionApril 4, 2024 | globenewswire.comANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with SarcoidosisApril 3, 2024 | globenewswire.comANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma SymposiumApril 2, 2024 | finance.yahoo.comANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should KnowMarch 27, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USPMarch 23, 2024 | finance.yahoo.comNYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist InvestorsMarch 21, 2024 | finance.yahoo.comANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should KnowMarch 19, 2024 | money.usnews.comANI Pharmaceuticals IncMarch 14, 2024 | stocknews.com3 Biotech Stocks to Jumpstart Your Portfolio GainsSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Confirmed)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees642Year FoundedN/APrice Target and Rating Average Stock Price Target$80.00 High Stock Price Target$83.00 Low Stock Price Target$77.00 Potential Upside/Downside+22.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.84 Trailing P/E Ratio77.89 Forward P/E Ratio18.43 P/E GrowthN/ANet Income$18.78 million Net Margins3.86% Pretax Margin4.08% Return on Equity18.06% Return on Assets8.38% Debt Debt-to-Equity Ratio0.66 Current Ratio3.57 Quick Ratio2.81 Sales & Book Value Annual Sales$486.82 million Price / Sales2.83 Cash Flow$6.40 per share Price / Cash Flow10.23 Book Value$21.13 per share Price / Book3.10Miscellaneous Outstanding Shares21,080,000Free Float18,402,000Market Cap$1.38 billion OptionableOptionable Beta0.79 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $1.31MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $751kMr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Mr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseDr. Mary Pao M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSKura OncologyNASDAQ:KURAGyre TherapeuticsNASDAQ:GYREMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 2,400 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Bought 46,008 shares on 4/24/2024Ownership: 0.398%Simplicity Wealth LLCBought 6,506 shares on 4/24/2024Ownership: 0.031%Muthusamy ShanmugamSold 16,809 sharesTotal: $1.10 M ($65.17/share)State of Alaska Department of RevenueSold 744 shares on 4/19/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price target for 2024? 4 brokers have issued 1-year target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $83.00. On average, they expect the company's stock price to reach $80.00 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2024? ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of 2024. Since then, ANIP shares have increased by 17.7% and is now trading at $64.90. View the best growth stocks for 2024 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 213,500 shares, an increase of 8.4% from the March 31st total of 197,000 shares. Based on an average daily trading volume, of 142,800 shares, the short-interest ratio is presently 1.5 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ANIP earnings forecast. How can I listen to ANI Pharmaceuticals' earnings call? ANI Pharmaceuticals will be holding an earnings conference call on Friday, May 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-938-2239 with passcode "4555224". How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The specialty pharmaceutical company earned $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a trailing twelve-month return on equity of 18.06%. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), First Trust Small Cap Growth AlphaDEX Fund (FYC), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals updated its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of 4.260-4.670 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $534.2 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.40%), Los Angeles Capital Management LLC (0.12%), Allspring Global Investments Holdings LLC (0.10%), State of Alaska Department of Revenue (0.04%), BTC Capital Management Inc. (0.04%) and Simplicity Wealth LLC (0.03%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
